Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. News Desk 2018 Message Board

Milestone Scientific Hosts Webcast with Top Key Op

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 617763
(Total Views: 177)
Posted On: 05/18/2017 11:00:02 AM
Avatar
Posted By: News Desk 2018
Milestone Scientific Hosts Webcast with Top Key Opinion Leader to Discuss Advantages of the CompuFlo(TM) Epidural Instrument

LIVINGSTON, NJ --(Marketwired - May 18, 2017) - Milestone Scientific Inc . ( NYSE MKT : MLSS ) , a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced a webcast presentation with Dr. Ralf Gebhard, a key opinion leader (KOL) in, Acute Pain Management and Regional Anesthesia sharing his personal and clinical trial experience with the CompuFlo Epidural Instrument and discussing its advantages and benefits in delivering superior clinical outcomes, objective documentation of clinical success, and physician productivity improvements. The webcast presentation is available on the Company's website at: http://www.milestonescientific.com/investors.html .

Dr. Ralf E. Gebhard is a Professor in the Department of Anesthesiology, Perioperative Medicine and Pain Management at the University of Miami. He also is the Chief of the Division of Acute Pain Management and Regional Anesthesia and serves as Associate Vice Chairman for Clinical Research. Dr. Gebhard joined the University of Miami in 2006 coming from The University of Texas‐Houston. In addition to his expertise in the area of Acute Pain Management, Dr. Gebhard has also proven himself to be an outstanding clinical researcher and scientist. He has conducted more than 40 clinical trials as a Principal Investigator and has received significant grants to support his research. His area of particular interest is related to peripheral nerve block safety and complications, as well as, acute pain management in the pediatric population Dr. Gebhard has published multiple book chapters and over 30 peer reviewed articles. He currently serves as a reviewer for numerous journals including Anesthesiology, Anesthesia and Analgesia and Regional Anesthesia and Pain Medicine. He is a frequent speaker at both national and international meetings and is considered an international expert in regional anesthesia and acute pain management.

About Milestone Scientific Inc .

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com .

The presentation contains forward-looking statements regarding the advantages of the CompuFlo Epidural Instrument. These statements represent the views and opinions of the presenter and may not represent the prevalent views and opinions of dental professionals, presently or in the future. The views and opinions of the presenter may be affected by future results of dental professionals utilizing the device, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward-looking statements in this presentation are based upon reasonable beliefs as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Please note that, from time to time, Milestone compensates its key opinion leaders for participation in and/or attendance at sponsored events on its behalf. Any such compensation is made without regard to the opinions and conclusions expressed by any such individual.

David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Tel: 212-671-1020



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us